TCP1 alpha/CCTA Antikörper (full length)

Produktnummer ABIN7879120

Der Maus Monoklonal anti-TCP1 alpha/CCTA Antikörper (Klon TP63-2428) (ABIN7879120) detektiert spezifisch TCP1 alpha/CCTA in FACS und IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für TCP1 alpha/CCTA Antikörper (full length) (ABIN7879120)

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TCP1 alpha/CCTA Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: TP63-2428

Produktdetails anti-TCP1 alpha/CCTA Antikörper

Bindungsspezifität: full length

Verwendungszweck: p63 Antibody

Aufreinigung: Protein G affinity chromatography

Immunogen: Full length human recombinant protein was used as the immunogen for the p63 antibody.

Isotyp: IgG2b, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the p63 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the p63 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu TCP1 alpha/CCTA

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Andere Bezeichnung: p63

Hintergrund: P63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands, however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90 % . Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80 %. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

UniProt: Q9H3D4